对EncephalAppStroop测试的外部验证,用于选非酒精性肝硬化症的肝脑病症最小患者
Ting-Ting Jiang1, Xiao-Li Liu1, Hao Yu1
1Center of Integrative Medicine, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing 100015, China.
World journal of hepatology
|January 2, 2025
概括
EncephalApp Stroop测试显示,在非酒精性肝硬化患者中查最小肝脑病变 (MHE) 是有前途的. 对于非酒精患者和酒精性肝硬化患者,建议使用不同的截止值,以确保准确的MHE诊断.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 神经科学是一个神经科学.
- 医疗技术 医疗技术 医学技术
背景情况:
- 神经认知障碍,包括最小的肝脑病变 (MHE),是肝脏疾病的常见并发症.
- EncephalApp Stroop测试为MHE查提供了一种节省时间的方法.
- 由于酒精性肝硬化和非酒精性肝硬化之间的差异,现有的MHE诊断切线可能无法普遍适用.
研究的目的:
- 为了验证EncephalApp Stroop测试用于MHE查,特别是在非酒精性肝硬化患者中.
- 在这个群体中确定EncephalApp Stroop测试的适当切割值.
主要方法:
- 在160名非酒精性肝硬化患者中对EncephalApp Stroop测试的外部验证.
- 将EncephalApp Stroop测试结果与心理测量肝脏脑病率 (PHES) 评分作为黄金标准进行比较.
- 使用曲线下的面积 (AUC),灵敏度,特异性和预测值来评估测试性能.
主要成果:
- 在非酒精性肝硬化患者中,EncephalApp Stroop测试在"关闭"时间 (AUC:0.85) 和"开启+关闭"时间 (AUC:0.85) 上表现良好.
- 最佳切断点被确定为"关机"时间>101.93秒和"开启+关机"时间>205.86秒.
- 该测试在这些截止点实现了0.84-0.90的灵敏度和0.71-0.77的特异性.
结论:
- EncephalApp Stroop测试是用于非酒精性肝硬化中MHE查的验证工具.
- 在非酒精患者和酒精性肝硬化患者中使用EncephalApp Stroop测试进行MHE查时,需要明确的切断值.
- 在所有慢性肝病患者广泛应用神经认知障碍查之前,这些发现至关重要.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Hepatic Encephalopathy
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...


